Prognostic Factors and Implantable Cardioverter-Defibrillator Outcomes in Transthyretin Cardiac Amyloidosis: A Comprehensive Retrospective Study
Reviews in Cardiovascular Medicine · 20.01.2026 · 27 (1)
DOI: 10.31083/rcm39760 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reviews in Cardiovascular Medicine, online erschienen am 20.01.2026. Verfasst von Mohammed Alaa Raslan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Mayo Clinic Arizona, Phoenix, AZ 85054, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Transthyretin (TTR) cardiac amyloidosis is a progressive cardiomyopathy with high mortality; however, the role of implantable cardioverter-defibrillators (ICDs) in this population remains unclear.
Methods
This retrospective cohort study included patients with confirmed TTR cardiac amyloidosis, with or without ICDs, from January 1, 2001, to December 31, 2024, across all three Mayo Clinic sites (Arizona, Florida, and Minnesota). Diagnosis was confirmed by endomyocardial biopsy or abnormal technetium pyrophosphate (PYP) scintigraphy. A 1:4 propensity score-matched cohort of non-ischemic cardiomyopathy (NICM) patients with ICDs served as a control group. The primary outcome was all-cause mortality, comparing transthyretin cardiac amyloidosis (TTR-CA) patients by ICD status and against matched NICM patients. Secondary analyses evaluated predictors of mortality, including the use of tafamidis and the indication for ICD (primary vs. secondary prevention). Kaplan–Meier and Cox regression analyses were used to assess predictors of survival and mortality.
Results
A total of 463 patients with confirmed TTR cardiac amyloidosis were included. The median follow-up duration was 7.4 years (interquartile range (IQR): 5.3–9.2 years) for the non-ICD group and 6.8 years (IQR: 4.5–9.0 years) for the ICD group. The median age was 74.5 years (IQR: 68.0–80.0 years), and 92.9% of patients were male. Among them, 206 (44.5%) received ICDs and 257 (55.5%) did not. ICD recipients were younger (71.0 vs. 77.0 years; p = 0.001) and had higher rates of hypertension (62.6% vs. 45.6%; p = 0.001), chronic kidney disease (CKD) (62.6% vs. 44.4%; p = 0.001), and diabetes (30.1% vs. 21.8%; p = 0.043). Median left ventricular ejection fraction was lower in the ICD groups (43% vs. 54%; p = 0.007), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were higher in the ICD group (2259.0 pg/mL vs. 1503.0 pg/mL; p = 0.007). Among ICD recipients, 157 (76.2%) received the device for primary prevention, while 48 (23.3%) received the ICD for secondary prevention. Appropriate shocks were delivered in 22 patients (10.6%), primarily for ventricular tachycardia (n = 18) and ventricular fibrillation (n = 4). Inappropriate shocks occurred in six patients (3.0%), and 12 patients (5.8%) experienced device-related complications. Over 10 years of follow-up, ICD implantation did not confer a survival benefit for patients with TTR-CA compared to those without an ICD (p = 0.74). In contrast, a 1:4 propensity-matched NICM cohort with ICDs, which had a median follow-up of 7.1 years (IQR: 4.6–8.8 years), showed significantly improved survival than TTR-CA patients with ICDs (p = 0.034). Among the TTR-CA patients with ICDs, neither the use of tafamidis (p = 0.10) nor the ICD indication (primary vs. secondary prevention; p = 0.85) influenced mortality. In the Cox regression analysis, predictors of mortality in TTR-CA patients included older age (hazard ratio (HR) 1.048; p = 0.001), CKD (HR 1.637; p = 0.029), troponin T >50 ng/L (HR 1.594; p = 0.031), NT-proBNP >3000 pg/mL (HR 1.514; p = 0.050), and ejection fraction
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Mayo Clinic Arizona, Phoenix, AZ 85054, USA.
- Department of Cardiovascular and Thoracic Surgery, Mayo Clinic Arizona, Phoenix, AZ 85054, USA.
- Department of General Surgery, Mayo Clinic Arizona, Phoenix, AZ 85054, USA.
ORCID-Profile: Dan Sorajja
Zitieren
APA
Raslan, M. A., Nabi, H. A., Odeh, N. B., Alatout, M. H., Baqal, O., Abbas, M. T., El Masry, H. Z., & Sorajja, D. (2026). Prognostic Factors and Implantable Cardioverter-Defibrillator Outcomes in Transthyretin Cardiac Amyloidosis: A Comprehensive Retrospective Study. Reviews in Cardiovascular Medicine, 27(1). https://doi.org/10.31083/rcm39760
Vancouver
Raslan MA, Nabi HA, Odeh NB, Alatout MH, Baqal O, Abbas MT, et al. Prognostic Factors and Implantable Cardioverter-Defibrillator Outcomes in Transthyretin Cardiac Amyloidosis: A Comprehensive Retrospective Study. Reviews in Cardiovascular Medicine. 2026;27(1). doi:10.31083/rcm39760
BibTeX
@article{Raslan2026,
author = {Raslan, Mohammed Alaa and Nabi, Hussein Abdul and Odeh, Nour B and Alatout, Mayar H and Baqal, Omar and Abbas, Mohammed Tiseer and El Masry, Hicham Z and Sorajja, Dan},
title = {Prognostic Factors and Implantable Cardioverter-Defibrillator Outcomes in Transthyretin Cardiac Amyloidosis: A Comprehensive Retrospective Study},
journal = {Reviews in Cardiovascular Medicine},
year = {2026},
volume = {27},
number = {1},
doi = {10.31083/rcm39760}
}
EUVIMED